Swiss National Bank Sells 300 Shares of Glaukos Co. (NYSE:GKOS)

Swiss National Bank lowered its stake in Glaukos Co. (NYSE:GKOS) by 0.3% during the 3rd quarter, Holdings Channel reports. The firm owned 98,400 shares of the medical instruments supplier’s stock after selling 300 shares during the quarter. Swiss National Bank’s holdings in Glaukos were worth $12,820,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. EFG Asset Management North America Corp. lifted its position in shares of Glaukos by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier’s stock worth $3,216,000 after buying an additional 128 shares in the last quarter. Values First Advisors Inc. bought a new stake in Glaukos in the 3rd quarter worth approximately $25,000. New York State Teachers Retirement System raised its holdings in shares of Glaukos by 0.4% during the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock worth $6,272,000 after acquiring an additional 200 shares in the last quarter. KBC Group NV boosted its position in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 201 shares during the last quarter. Finally, Inspire Investing LLC grew its holdings in shares of Glaukos by 6.9% in the third quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock valued at $416,000 after purchasing an additional 206 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. This trade represents a 2.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the sale, the director now owns 32,336 shares of the company’s stock, valued at $4,225,345.12. This represents a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by company insiders.

Glaukos Price Performance

Shares of GKOS stock opened at $144.00 on Friday. The stock has a 50 day moving average price of $132.40 and a 200 day moving average price of $123.58. Glaukos Co. has a 52-week low of $59.22 and a 52-week high of $146.09. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm has a market capitalization of $7.94 billion, a P/E ratio of -47.68 and a beta of 1.02.

Glaukos (NYSE:GKOS) last released its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.20. The business had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business’s revenue for the quarter was up 23.9% compared to the same quarter last year. During the same period last year, the company earned ($0.50) earnings per share. As a group, sell-side analysts predict that Glaukos Co. will post -1.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on GKOS shares. Stifel Nicolaus upped their price target on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. upped their target price on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Truist Financial lifted their price target on Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Needham & Company LLC upped their price objective on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Finally, Piper Sandler set a $140.00 target price on Glaukos in a report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $134.55.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.